Last updated 5 days ago
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
40 patients around the world
Available in United States, Brazil, Peru, Spain
Hoffmann-La Roche
3Research sites
40Patients around the world
This study is for people with
Lupus
Lupus nephritis
Requirements for the patient
To 17 Years
All Gender
Medical requirements
Sites
SER - Serviços Especializados em Reumatologia da Bahia
Recruiting
SER - Serviços Especializados em Reumatologia da Bahia
Recruiting
Hospital das Clínicas da Faculdade de Medicina da São Paulo - USP
Recruiting
Hospital das Clínicas da Faculdade de Medicina da São Paulo - USP
Recruiting
Hospital Universitario Dr. José Eleuterio González
Recruiting
Hospital Universitario Dr. José Eleuterio González
Recruiting
StudyPOSTERITY
SponsorHoffmann-La Roche
Study typeInterventional
Conditions
Lupus nephritis
Requirements
To 17 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05039619
